AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding

The drugmaker AstraZeneca has paused a planned £200m investment in its Cambridge research site, completing a depressing week for the UK pharmaceutical industry.

The decision by Britain’s biggest company means none of its much-trumpeted £650m investment package in the UK – which was originally announced in March 2024 – is currently proceeding.